A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia

Recruiting

Phase 2

Ivosidenib, Azacitidine, VenetoclaxA Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia

Sponsor:

Memorial Sloan Kettering Cancer Center

Code:

NCT07392242

Conditions

Acute Myeloid Leukemia

Eligibility Criteria

Sex: All

Age: 60+

Healthy Volunteers: Not accepted

Interventions

Ivosidenib

Azacitidine

Venetoclax

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-02-08. This information was provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center on 2026-02-06.